1,721,043 research outputs found
Corrigendum
No full textCorrigendum to ‘Harnessing gemcitabine metabolism: a step towards personalized medicine for pancreatic cancer’ by Muhammad Saif, Yoomi Lee and Richard Kim, Therapeutic Advances in Medical Oncology 2012; 4(6):341-6. DOI: 10.1177/1758834012453755 . The corresponding author would like to note their name should be recognized as Muhammad Wasif Saif (Saif MW) and not as Muhammad Saif (Saif M) in this article
Management of a Patient with Metastatic Colorectal Cancer and Liver Metastases
Full text linkLiver metastases are commonly encountered in patients presenting with metastatic colorectal cancer (mCRC); resection is the treatment of choice. A number of systemic treatment options are currently available for such patients, including the use of 5-fluorouracil-based chemotherapies and oxaliplatin (e.g., FOLFOX) in combination with biologic agents that target angiogenesis (e.g., bevacizumab). For patients with progression following first-line treatment, current second-line options include a change in chemotherapy with bevacizumab (for patients who did or did not receive prior bevacizumab) or FOLFIRI in combination with aflibercept, a more recently approved antiangiogenesis therapy. Neurotoxicity is a well-established adverse event of oxaliplatin-based therapy. The current case details an mCRC patient with liver metastases who was treated with a capecitabine and oxaliplatin regimen (XELOX), and experienced two episodes of transient cortical blindness possibly related to oxaliplatin. After disease progression, the patient was switched to a regimen of FOLFIRI and aflibercept and did well on this second-line regimen
First Case of Topical 5-FU Therapy for Cutaneous Metastasis in a patient with Colon Cancer
No full text
Ethnic Differences in Hematologic Toxicity from Imatinib in Patients with Gastrointestinal Stromal Cell Tumor (GIST)
No full text
Telotristat ethyl: proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea
No full text- …
